QIAGEN sells synthetic DNA business in management buyout.
For both the third and fourth quarters QIAGEN revised the high end of its operating margin upward by one percentage point and revised its EPS downward by one cent According to QIAGEN, the spinout will improve its margins, lead to lower volatility and increased brand equity. Operon will consist of QIAGEN's former custom and modified oligo businesses, shelf products (Array Ready Oligo Sets) and antibody and peptide business, and includes the transfer of QIAGEN Sciences KK (formerly Sawady) QIAGEN Operon GmbH (Cologne) and QIAGEN Operon's Alameda, California and Germantown, Maryland operations QIAGEN noted that the Operon business is different due to its mostly nonproprietary products, custom-made products, fast turn around times and low competitive barriers QIAGEN states that Operon is the number two competitor in the oligo market in the US, Europe and Japan.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Executive briefing: news, trends & market intelligence for instrument executives|
|Publication:||Instrument Business Outlook|
|Date:||Jun 30, 2004|
|Previous Article:||Applied bio gets injunction against Bio-Rad and grants Cepheid license.|
|Next Article:||Teledyne completes ISCO acquisition and exits SFE business.|